Saturday 17 October 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024. In the quarter to June 2026, revenue grew 24.1%, EPS grew 39.1% and free cash flow grew 40.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

316.58 13.42 −4.07%

Follow KRYS

Alert me

Market cap: $9.8B
P/E: 38.3×
Fwd P/E: 38.6×
Dividend yield: —
F-score: 7/9
Altman Z: 39.03
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 105.27

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	—	4	3	—	1	3	—	1	2	—

Insider Ownership 12.05%

Capital & Financial Ratios $m

Market Cap 9,770.00

Revenue 440.48

Net Income 241.46

Free Cash Flow 257.78

Net Debt (845.63)

Current Ratio 8.32

Debt/Equity 0.00

P/E ratio 38.28

Fwd P/E 38.60

P/S ratio 21.22

P/B ratio 6.88

Past 5Y EPS Growth —

This Y EPS Growth 8.20%

Next Y EPS Growth 23.03%

Next Y revenue growth 28.03%

Next 5Y EPS Growth 24.30%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 94.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	532	598	828	846
Receivables	42	105	127	139
Inventory	7	27	40	46
Other	—	—	—	—
	588	742	1,025	1,060

	2023	2024	2025	Q'26
Payables	4	5	3	7
ST’ Debt	—	—	—	—
Other	—	—	—	—
	33	102	103	127

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	33.09%	32.67%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	116	119	—	—	—
’25	88	96	98	107	389
’24	45	70	84	91	291

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	80	75	—	—	—
’25	31	53	40	78	201
’24	16	(4)	59	53	123
’23	(26)	(34)	(21)	(7)	(89)
’22	(15)	(43)	(20)	(22)	(101)
’21	(10)	(10)	(7)	(21)	(48)
’20	(6)	(5)	(7)	(8)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	73	71	—	—	—
’25	25	51	38	75	189
’24	15	(5)	58	52	119
’23	(32)	(37)	77	(9)	(1)
’22	(33)	(60)	(34)	(28)	(154)
’21	(12)	(14)	(28)	(62)	(116)
’20	(8)	(7)	(11)	(15)	(41)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.83	1.79	—	—	—
’25	1.20	1.29	2.66	1.70	6.84
’24	0.03	0.53	0.91	1.52	3.00
’23	(1.76)	(1.25)	2.79	0.30	0.39
’22	(1.99)	(1.10)	(1.17)	(1.25)	(5.49)
’21	(0.74)	(0.74)	(0.70)	(0.94)	(3.13)
’20	(0.31)	(0.37)	(0.49)	(0.53)	(1.71)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	8.03	8.61	18.50	33.09	38.86	47.67	69.81	107.50	122.80	Analyst estimates 2026–2028 Powerpack
	High	—	11.98	28.75	66.50	66.85	102.99	85.11	132.68	219.34	265.92
People
People	Employees	7	12	37	53	75	119	210	229	275	295
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22	1.06	1.32
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	51	291	389
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	93.90	93.09	94.08
	EBT	(1)	(8)	(11)	(19)	(32)	(70)	(140)	13	95	189
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25.44	32.82	48.69
	Net income	(1)	(8)	(11)	(19)	(32)	(70)	(140)	11	89	205
	Depreciation	0	0	0	1	2	3	3	6	7	7
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.87	10.16	13.44
	Earnings	(1.31)	(1.48)	(0.97)	(1.20)	(1.71)	(3.13)	(5.49)	0.40	3.12	7.08
	Cash flow	(1.49)	(0.73)	(0.84)	(1.18)	(1.39)	(2.16)	(3.95)	(3.27)	4.32	6.94
	Capex	(0.02)	(0.04)	(0.20)	(0.40)	(0.79)	(3.08)	(2.08)	3.25	(0.15)	(0.40)
	Free cash flow	(1.51)	(0.76)	(1.04)	(1.58)	(2.18)	(5.24)	(6.02)	(0.02)	4.17	6.54
	Book value	0.33	9.23	10.11	12.76	15.55	26.74	20.49	28.68	33.10	42.14
	Shares, m	1	5	11	16	19	22	25	27	29	29
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	694.22	50.54	34.82
	P/S	—	—	—	—	—	—	—	0.00	15.42	18.34
	P/B	—	—	—	—	—	—	—	4.36	4.73	5.85
	EV/Sales	—	—	—	—	—	—	—	0.00	13.36	16.21
	EV/FCF	—	—	—	—	—	—	—	(4,744.59)	32.57	33.31
Cash, $m
Cash, $m	Operating cash flow	(1)	(4)	(9)	(19)	(26)	(48)	(101)	(89)	123	201
	Capex	0	0	(2)	(6)	(15)	(68)	(53)	88	(4)	(12)
	Free cash flow	(1)	(4)	(12)	(25)	(41)	(116)	(154)	(1)	119	189
Balance, $m
Balance, $m	Working capital	2	49	110	193	260	417	355	555	640	922
	Total debt	2	—	—	3	3	7	7	—	—	—
	Net debt	0	(50)	(112)	(194)	(271)	(438)	(379)	(532)	(598)	(828)
	Shareholders’ equity	0	49	113	203	292	594	522	779	946	1,220
Returns, %
Returns, %	ROA	(4.40)	(30.29)	(13.10)	(11.74)	(12.38)	(14.85)	(23.63)	1.59	9.51	17.14
	ROIC	(341.81)	0.00	(508.36)	(149.54)	(99.05)	(27.45)	(63.43)	(27.80)	11.78	25.73
	ROE	(4.76)	(32.76)	(13.39)	(12.08)	(13.00)	(15.71)	(25.09)	1.68	10.34	18.91

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
PCVX Vaxcyte, Inc.	$10.3B	— (loss-making)	—	—	n/m	−92.55% (below 0%: shrinking)	0.00%	0.00%	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
CAI Caris Life Sciences,�Inc.	$9.0B	81.3×	163×	+45.38% (above 0%: growing)	n/m	+8.47% (above 0%: growing)	68.10%	10.21%	Compare
CYTK Cytokinetics, Incorporated	$8.9B	— (loss-making)	— (loss-making)	−57.13% (below 0%: shrinking)	n/m	−24.02% (below 0%: shrinking)	80.46%	(625.95%)	Compare
PTGX Protagonist Therapeutics, Inc.	$8.8B	106×	25.0×	+3,749.17% (above 0%: growing)	n/m	+839.65% (above 0%: growing)	100.00%	74.37%	Compare
Median of peers	$9.6B	106×	25.0×	+71.17%	—	+9.22%	84.74%	(7.73%)

All 614 Biotechnology stocks →

Krystal Biotech, Inc. (KRYS) key facts

Strength: Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
Strength: Net income was $204.8 million, or $7.08 per share (basic), a net margin of 52.6%.
Krystal Biotech, Inc. (KRYS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KRYS traded at $316.58, a market capitalization of $9.8 billion.
At that price the stock trades at 38.3× trailing-twelve-month earnings and 21.2× sales.
Return on equity was 18.9% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 39.03 (safe zone) for fiscal 2025.